NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

330.60 -5.80 (-1.72%)

4.0M NSE+BSE Volume

NSE 05 Jun, 2025 3:31 PM (IST)

39,691.8

Market Cap

Market Leader

1.2

Beta 1Year

Very High Volatility

Regulatory Approval

Biocon receives CDSCO nod for Liraglutide, used to treat Type 2 diabetes in adults and children See details

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

04 May 2015

330.60

-1.72%

Biocon 4May2015

Buy: Biocon Ltd.

Phillip Capital

Biocon Ltd. is trading below all available SMAs

Biocon Ltd.

24 Apr 2015

330.60

-1.72%

In fact, the company offers 20mn shares (10%) of Syngene to public and reserved 2mn sharesforBioconShareholders.ItplanstooffersharestoBioconshareholdersandretail investorsatadiscounttoofferprice.PostissueBioconwillhold74.5%stakeinSyngene....

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Is Biocon Ltd. worth buying?

716 Votes:

Buy 75.14%

Sell 16.34%

Hold 8.52%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf